KAZIA THERAPEUTICS LIMITED.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer 2021-11-16 00:00
PNOC Study in Childhood Brain Cancer Enrols First Patient 2021-11-11 21:00
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference 2021-09-11 00:30
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs 2021-06-30 22:00
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma 2021-06-15 22:00
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient 2021-06-07 20:00
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE 2021-04-19 17:54
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company 2021-03-29 17:43
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB 2021-03-02 07:00
Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG 2020-12-10 12:51
Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals 2020-12-09 07:49
Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma 2020-11-18 07:39
Kazia Executes Agreement To Commence GBM Agile Pivotal Study 2020-10-16 07:30
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma 2020-09-22 09:21
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG 2020-08-24 09:14
US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma 2020-08-20 08:35
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG 2020-08-07 08:30
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs 2020-06-22 12:39
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal 2020-06-01 08:45
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study 2020-04-07 20:00
1 2 3 4 5 7